The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1485
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.

TREATMENT OF PAH — Monotherapy with an oral drug is usually recommended for initial treatment of PAH. Drugs approved by the FDA for this indication include phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists, and a guanylate cyclase stimulator.1 Patients with more advanced disease may be treated with a prostacyclin (see Table 2). The FDA recently approved the oral selective IP prostacyclin receptor agonist selexipag (Uptravi) for treatment of PAH; it will be reviewed in a future issue.

Combination Therapy – Limited data are available on the effectiveness of combination therapy ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Article code: 1485b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian